We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
United Kingdom - August 10 2009
The recently released UK "Life Sciences Blueprint" (the Blueprint), which provides an important roadmap for future government investment in, and regulation of, the pharmaceutical and biotechnology industries, signals a significant shift in cost-effectiveness requirements for pharmaceutical, biologic, and device manufacturers.
